MGAM (M-Gam) develops small molecules with established human exposure into defined rare neurological, neurodevelopmental, and metabolic indications — trading discovery risk for regulatory execution. Alongside the programs, the group builds software of its own, and gives it away.
Most of what makes rare-disease development expensive is discovery risk — and most of that risk is already retired for a molecule that has been in people.
Each candidate is a small molecule already administered to people, with safety and pharmacokinetics characterized in the published record. The questions that consume the largest share of a discovery-stage budget are substantially answered before a program begins.
Programs are advanced to FDA designation first. A designation is a regulatory position with standing — orphan exclusivity, fee relief, formal agency engagement — and it is reached on a small fraction of what a registrational trial costs.
Each program targets one indication with a defined patient population and a documented unmet need, rather than a platform seeking an application. Narrow scope is what keeps the development path legible to a reviewer and to a partner.
The drug programs are one half of MGAM. The other is software the group writes itself and releases free under its own name — narrow tools built to do one job each, for the kind of measurement the programs depend on.
MGAM works with clinical collaborators, patient organisations, and commercial partners on individual programs, and with laboratories and research groups on its software. For program-level diligence, licensing discussions, software enquiries, or corporate matters, write to us directly.